Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704510 | 0.89 | PHGDH (0.59) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL4251838 | 0.85 | HPGD (0.67) | HPGDALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL10720943 | 0.84 | PHGDH (0.81) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL6112281 | 0.83 | HPGD (0.69) | HPGDALDH1A1SMN1; SMN2MAPTPOLB | |
| SCHEMBL15976788 | 0.82 | PHGDH (0.63) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL9792247 | 0.82 | HPGD (0.79) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL5115066 | 0.82 | L3MBTL1 (0.72) | HPGDALDH1A1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL28284713 | 0.81 | PHGDH (0.61) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL27771521 | 0.79 | PHGDH (0.59) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28296651 | 0.79 | HPGD (0.86) | PHGDHHPGDALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216432-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | KING'S COLLEGE LONDON (GB) | 2020-07-09 | — | — | US | disclosed |
| EP-3665164-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Kings College London (GB) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019030538-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | KING'S COLLEGE LONDON (GB) | 2019-02-14 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080004263-A1 | Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof | ARENA PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1805142-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Reddy US Therapeutics, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006048331-A1 | 11β-HSD1 INHIBITORS | EVOTEC AG (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006034474-A2 | NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | REDDY US THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005087765-A1 | LIGANDS OF FOLLICLE STIMULATING HORMONE RECEPTOR AND METHODS OF USE THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PHGDH 3961/4885HPGD 3066/4885ALDH1A1 3748/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | PHGDH 1239/4885HPGD 842/4885ALDH1A1 1929/4885 |
| US-20200216432-A1 | SULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | JAK2, STAT3, STAT5A | PHGDH 2107/4885HPGD 2688/4885ALDH1A1 1467/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | PHGDH 1239/4885HPGD 842/4885ALDH1A1 1929/4885 |
| US-20080004263-A1 | Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof | FSHR, GNRHR, LHCGR | PHGDH 4211/4885HPGD 1248/4885ALDH1A1 1620/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PHGDH 2568/4885HPGD 3064/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.